Contrasting Nanosphere (NASDAQ:NSPH) & Its Peers

Nanosphere (NASDAQ: NSPH) is one of 80 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it compare to its rivals? We will compare Nanosphere to similar businesses based on the strength of its profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Nanosphere and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nanosphere 0 0 0 0 N/A
Nanosphere Competitors 326 1962 3476 111 2.57

As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 3.51%. Given Nanosphere’s rivals higher possible upside, analysts clearly believe Nanosphere has less favorable growth aspects than its rivals.

Profitability

This table compares Nanosphere and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nanosphere -99.68% -232.37% -65.52%
Nanosphere Competitors -316.68% -23.94% -10.20%

Institutional & Insider Ownership

50.8% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 18.8% of shares of all “Advanced Medical Equipment & Technology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Nanosphere and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Nanosphere N/A N/A -0.31
Nanosphere Competitors $2.14 billion $234.27 million -90.90

Nanosphere’s rivals have higher revenue and earnings than Nanosphere. Nanosphere is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Nanosphere rivals beat Nanosphere on 6 of the 8 factors compared.

About Nanosphere

Nanosphere, Inc. is engaged in developing, manufacturing and marketing an advanced molecular diagnostics platform, the Verigene System, which enables genomic and protein testing on a single platform. The Verigene System includes a molecular diagnostics workstation that is a single use consumable for testing. The Verigene System consists of a microfluidics processor, a touchscreen reader and disposable test cartridges. The Company is focused on the infectious disease diagnostics market. Its Infectious Disease Assays include Respiratory Virus with Sub-Typing (RV+); Respiratory Pathogens/Expanded Panel (RP Flex); Bloodstream Infection (BSI) Panels, which include Blood Culture – Gram Positive (BC-GP), Blood Culture – Gram Negative (BC-GN) and Blood Culture – Yeast (BC-Y); C. difficile (CDF), and Enteric Panel (EP). Its Human Pharmacogenetic Assays include Hypercoagulation (FV, FII, MTHFR Panel) and CYP2C19 Genetic Variance. It is focused on the infectious disease diagnostics market.

Receive News & Ratings for Nanosphere Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanosphere and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets


Leave a Reply

 
© 2006-2018 BBNS.